



RTP TV

TRIPLE-NEGATIVE BREAST CANCER: CURRENT CLINICAL MANAGEMENT

Select Publications

Aebi S et al. **Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.** *Ann Oncol* 2010;21(Suppl 5):v9-v14. **Abstract**

Allred DC et al. **The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer.** *Breast Cancer Res* 2004;6(60):240-5. **Abstract**

Balmana J et al. **BRCA in breast cancer: ESMO clinical practice guidelines.** *Ann Oncol* 2010;21(Suppl 5):v20-v22. **Abstract**

Bear HD et al. **The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40.** *Proc ASCO* 2011;Abstract LBA1005.

Brufsky A et al. **Impact of bevacizumab (BEV) on efficacy of second-line chemotherapy (CT) for triple-negative breast cancer (TNBC): Analysis of RIBBON-2.** *Proc ASCO* 2011;Abstract 1010.

Burstein HJ. **Bevacizumab for advanced breast cancer: All tied up with a RIBBON?** *J Clin Oncol* 2011;29(10):1232-5. **Abstract**

Cardoso F et al. **Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.** *Ann Oncol* 2010;21(Suppl 5):v15-v19. **Abstract**

Foulkes WD et al. **Triple-negative breast cancer.** *N Engl J Med* 2010;363(20):1938-48. **Abstract**

Ganz PA, Cole SW. **Expanding our therapeutic options: Beta blockers for breast cancer?** *J Clin Oncol* 2011;29(19):2612-6. **Abstract**

Gelmon KA et al. **Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer.** *Proc ASCO* 2010;Abstract 3002.

Gerber B et al. **Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 686 triple-negative primary breast cancers: Secondary endpoint analysis of the GeparQuinto study (GBG 44).** *Proc ASCO* 2011;Abstract 1006.

Goldhirsch A et al. **Thresholds for therapies: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009.** *Ann Oncol* 2009;20(8):1319-29. **Abstract**

Li CI et al. **Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998.** *J Clin Oncol* 2003;21(1):28-34. **Abstract**

Melhem-Bertrandt A et al. **Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer.** *J Clin Oncol* 2011;29(19):2645-52. **Abstract**

Miles D et al. **Plasma biomarker analyses in the AVADO Phase III randomized study of first-line bevacizumab + docetaxel in patients with human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer.** *San Antonio Breast Cancer Symposium* 2011;Abstract P2-16-04.

O'Shaughnessy J et al. **A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).** *Proc ASCO* 2011;Abstract 1007.

Prat A, Perou CM. **Deconstructing the molecular portraits of breast cancer.** *Mol Oncol* 2011;5(1):5-23. **Abstract**

Ruiz-Borrego M et al. **Local versus central laboratory discrepancies in the determination of triple-negative breast cancer (TNBC) status in a large phase III (CIBOMA/2004-01/GEICAM/2003-11) trial assessing adjuvant capecitabine (C) maintenance therapy after standard chemotherapy (CT) in early breast cancer (EBC) patients (pts).** *Proc ASCO* 2011;Abstract 1022.

Siegel R et al. **Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths.** *CA Cancer J Clin* 2011;61(4):212-36. **Abstract**

Tutt A et al. **Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial.** *Lancet* 2010;376(9737):235-44. **Abstract**

Von Minckwitz G et al. **Neoadjuvant chemotherapy with or without bevacizumab: Primary efficacy endpoint analysis of the GEPARQUINTO study (GBG 44).** *San Antonio Breast Cancer Symposium* 2010;Abstract S4-6.

Yaziji H et al. **HER-2 testing in breast cancer using parallel tissue-based methods.** *JAMA* 2004;29(16):1972-7. **Abstract**

CALGB-40502/NCCTG N063H: A Phase III trial of bevacizumab with paclitaxel, nab paclitaxel or ixabepilone in patients with Stage IIIC-IV breast cancer. NCT00785291.

CALGB-40603 — Paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide in treating patients with breast cancer that can be removed by surgery. NCT00861705.